Cellebrite DI Ltd. has announced impressive financial results for the third quarter of 2026, showcasing significant growth in annual recurring revenue (ARR) and adjusted EBITDA. This performance is particularly noteworthy as it reflects the company's successful execution of its strategic initiatives in a competitive landscape.

In its latest filing, Cellebrite reported a 20% year-over-year increase in ARR, reaching $528.5 million. The company also achieved a net income of $26.7 million, with non-GAAP net income at $45.6 million and an adjusted EBITDA of $53.6 million, resulting in a 36% adjusted EBITDA margin. This strong financial performance is a clear indicator of Cellebrite's growing market presence and operational efficiency.

Background

Cellebrite DI Ltd. operates within the prepackaged software industry, specifically focusing on AI-powered digital investigative and intelligence solutions. The company is publicly traded on the Nasdaq under the ticker symbol CLBT. It was established to provide innovative solutions for both public and private sectors, enhancing investigative capabilities and operational efficiency.

According to recent filings, Cellebrite has been active in the market, indicating a strong commitment to growth and innovation. The company filed its latest report on November 12, 2026, which included key financial data and strategic updates.

What the Filing Says

The filing states, "Cellebrite executed better in the third quarter, with ARR, revenue and adjusted EBITDA all finishing above our targets." This highlights the company’s successful execution of its business strategy and its ability to exceed expectations in a challenging market environment.

Impact

The results from Cellebrite may significantly affect various stakeholders, including investors, competitors, and customers. Investors may view the strong performance as a positive sign of the company's future potential, while competitors in the prepackaged software sector may need to reassess their strategies to keep pace with Cellebrite's advancements and market share growth.

What's Next

Cellebrite has raised its adjusted EBITDA outlook for the full year 2026, now expecting between $163 million and $166 million. The company is also planning to host a live conference call to discuss these results and its full-year outlook, which will provide further insights into its strategic direction and market positioning.

The filing does not specify any immediate next steps beyond the conference call.